2020年4月21日

大流行期间心脏导管STEMI激活下降

(HealthDay)-根据4月10日在线发表的研究信,在COVID-19大流行期间,美国心脏导管实验室的ST段抬高型心肌梗死(STEMI)激活减少了38%。 美国龋病学杂志.

Santiago Garcia, M.D., from the Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, 和 colleagues quantified STEMI activations for nine high-volume (>100 primary percutaneous coronary interventions [PPCIs] per year) U.S. cardiac catheterization laboratories from Jan. 1, 2019, to March 31, 2020. March 1, 2020 was identified as the beginning of the "after COVID" (AC) period. Monthly total 和 average number of STEMI activations for each 在“ COVID之前”(BC)和AC进行比较。

The researchers found a 38 percent decrease in STEMI activations from the BC period to AC period. Across sites, there was a mean of 23.6 activations per month (combined, >180 STEMI activations) in the BC period, while there was 只要 a mean of 15.3 activations per month in the AC period (138 activations total). The decrease in STEMI PPCI activations may be due to avoidance of medical care due to social distancing 要么 concerns of contracting COVID-19 in the 医院, STEMI misdiagnosis, 和 increased use of pharmacological reperfusion due to COVID-19.

加西亚在一份声明中说:“尽管我们都担心COVID-19的暴露,但患者还需要知道避免护理和治疗对于某些急性心血管疾病(例如心脏病发作)可能是危险的。” “在这些情况下,时间是关键,全国各地的医院都在遵循谨慎的程序,以确保患者免受COVID-19暴露的危害,同时为其他心血管疾病提供挽救生命的治疗方法。”



版权所有©2020 健康日。版权所有。

引文: 大流行期间(2020年4月21日)心脏导管实验室的STEMI活性下降 2021年1月23日检索 from //xasqxhb.com/news/2020-04-cardiac-cath-lab-stemi-pandemic.html
本文件受版权保护。除了出于私下学习或研究目的进行的任何公平交易外, 未经书面许可,不得复制部分内容。内容仅供参考。

用户评论